Physician profile
Alfonso Antonio Quant
NPI 1700949716
$1,025.73
in general payments reported to CMS, 2019-2025
10 companies · $206 in 2025
The $206 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $99.83 · 2023: $398 · 2024: $200 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $803.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $600.77 | 2021-2025 | Bexsero, Penmenvy |
| Pfizer INC. | $105.12 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $103.38 | 2022-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Cranial Technologies, INC | $42.91 | 2023-2024 | Doc Band |
| Alk-Abello, INC | $42.48 | 2024-2025 | Odactra, Grastek, Ragwitek |
| Phadia US INC. | $34.66 | 2022-2023 | Immunocap |
| Seqirus USA INC | $27.73 | 2023 | Flucelvax Quadrivalent |
| Sobi, INC | $27.15 | 2022 | |
| Cipher Pharmaceuticals US LLC | $22.44 | 2025 | Spinosad, Natroba |
| Sanofi Pasteur INC. | $19.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfonso Quant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.